U.S. markets closed
  • S&P Futures

    3,604.00
    +28.00 (+0.78%)
     
  • Dow Futures

    29,810.00
    +264.00 (+0.89%)
     
  • Nasdaq Futures

    11,973.75
    +68.50 (+0.58%)
     
  • Russell 2000 Futures

    1,838.30
    +21.20 (+1.17%)
     
  • Crude Oil

    43.47
    +0.41 (+0.95%)
     
  • Gold

    1,822.80
    -15.00 (-0.82%)
     
  • Silver

    23.42
    -0.21 (-0.90%)
     
  • EUR/USD

    1.1848
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3329
    +0.0007 (+0.05%)
     
  • USD/JPY

    104.5660
    +0.0780 (+0.07%)
     
  • BTC-USD

    18,343.21
    +10.71 (+0.06%)
     
  • CMC Crypto 200

    368.12
    +6.69 (+1.85%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,228.49
    +701.12 (+2.75%)
     

Karyopharm Therapeutics: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) increased 10.3% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 8.96% over the past year to ($0.73), which missed the estimate of ($0.72).

Revenue of $21,333,000 higher by 62.24% year over year, which missed the estimate of $21,450,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 02, 2020

View more earnings on KPTI

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2451/38092

Technicals

Company's 52-week high was at $29.61

52-week low: $11.31

Price action over last quarter: down 7.99%

Company Profile

Karyopharm Therapeutics Inc is a pharmaceutical company. The company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer. Its pipeline products of the company include Oral Selinexor, Oral Eltanexor, Oral Dual Inhibitor of PAK4 and NAMPT and Oral Verdinexor, as well as its lead product, include XPOVIO.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.